Oral Care Before Cancer Treatment

Home Forums Oral & Maxillofacial surgery Oral Care Before Cancer Treatment

Welcome Dear Guest

To create a new topic please register on the forums. For help contact : discussdentistry@hotmail.com

Currently, there are 0 users and 1 guest visiting this topic.
Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • #10626
    DrAnil
    Offline
    Registered On: 12/11/2011
    Topics: 147
    Replies: 101
    Has thanked: 0 times
    Been thanked: 0 times

    Cancer. The New Oxford American Dictionary defines it as “the disease caused by an 

    Cancer. The New Oxford American Dictionary defines it as “the disease caused by an 

    uncontrolled division of abnormal cells in a part of the body;” but for the millions of 

    people it has touched, cancer is so much more. 

    Cancer is a constant unwanted companion that 

    opens the door to an unchosen journey and 

    demands to be followed.

     

    Cancer is a constant 

    unwanted companion that 

    alters the well-being of those it afflicts. Modern 

    treatment regimens given to combat this

    disease come with a host of deleterious side 

    effects, many of which occur in the mouth. 

     

     

    Dentists, dental hygienists and dental auxiliaries 

    are in a unique and necessary position to make

    a positive impact in the lives of patients battling 

    cancer. 

     

    Making a difference begins with a desire to help and a willingness to take a risk. It is 

    followed by a commitment to learn about the unique oral health care needs of patients 

    engaged in the fight of their lives and put into practice skills that can literally provide 

    comfort and hope. We, as dental professionals, can and should be a part of a 

    comprehensive cancer care team for an ever-growing number of people facing cancer.

     

    DENTAL ONCOLOGY 

     

    Dental oncology is a focus of dentistry dedicated to meeting the unique dental and oral 

    health care needs that arise as a result of cancer therapy. It is an area of oral medicine 

    devoted to improving the well-being and quality of life of people battling cancer. Dental 

    oncology goes beyond the scope of general dental treatment to include management of 

    the soft tissues of the mouth and care for oral side effects specific to cancer therapy. A 

    dental professional knowledgeable in dental oncology plays an important role 

    throughout cancer treatment by preventing and managing mouth sores, dental needs, 

    oral pain and infections. As a member of the patient’s oncology care team, the dental 

    professional communicates directly with the medical oncologist, radiation oncologist and 

    other team members to provide optimal comprehensive care before, during, and after 

    cancer treatments. 

     

    Ideally, a patient’s relationship with a dental professional begins as soon as possible 

    after receiving the diagnosis of cancer. Most of the present-day treatments for cancer 

    involve the administration of cytotoxic drugs, radiation, myelosuppressive treatments or 

    some combination thereof. Having a baseline assessment completed before the 

    implementation of immunosuppressive therapies allows the dental professional to have 

    a pre-treatment reference point to compare oral and systemic health at future visits. 

     

    For the newly diagnosed patient with cancer who has not received regular dental and 

    oral health care, a prompt visit to the dentist’s office also allows for immediate attention 

    to unaddressed periodontal issues and unresolved dental needs before 

    immunosuppression begins. During cancer treatments, bacterial components of 

    calculus, dental plaque and oral biofilm can easily become vehicles for bacteremia or 

    oral infections. Properly addressing these oral health concerns at this pre-treatment 

    stage can prevent or significantly reduce the severity of oral issues that could 

    complicate or even interrupt the patient’s cancer treatment schedule. 

     

    ORAL HEALTH CARE BEFORE CHEMOTHERAPY 

     

    Chemotherapy is the treatment of choice for a wide range of cancers. It can be used 

    either alone or in combination with other treatment modalities. The goal of 

    chemotherapy is to eradicate the rapidly dividing cancerous cells, but unfortunately 

    these drugs often cannot differentiate between cancer cells and other types of cells that 

    divide rapidly under normal conditions within the body. These cells include bone 

    marrow, hair, and the mucosa of the entire gastrointestinal tract, including the mouth.

     

    Because chemotherapeutic 

    agents are used to combat 

    cancers of all types, the dental 

    professional is needed to care for 

    patients with most kinds of 

    cancer, not just malignancies 

    relevant to structures within the 

    head or neck. 

     

    Because chemotherapeutic 

    agents are used to combat cancers of all 

    types, the dental professional is needed to 

    care for patients with most kinds of cancer, 

    not just malignancies relevant to structures 

    within the head or neck. 

     

    Optimally, the patient should see a dental 

    professional well enough in advance so that 

    all 

    dental procedures can be completed one 

    week before beginning chemotherapy. At a 

    minimum, dental procedures that might 

    introduce bacteria into the bloodstream 

    should be completed in this timeframe. 

    Close communication with the medical 

    oncologist is of paramount importance as 

    each member of the oncology team needs 

    to be aware of the scheduling of all 

    care 

    related to the patient. Communication 

    should include a summary of the present 

     

    oral health of the patient, a treatment plan of essential dental care, and an anticipated 

    timeline of when that care can be completed. The dental professional should also 

    confirm that the medical colleagues on the oncology team understand the nature of 

    anticipated oral complications during treatment and be prepared to function as the 

    expert able to address those oral health issues.

     

    Dental management before chemotherapy should include a thorough baseline dental 

    and periodontal assessment with close attentions paid to conditions that could be 

    problematic during times of immunosuppression. Preemptive measures should be 

    taken to correct or remove any possible sources of oral trauma. These might include 

    broken teeth or ill-fitting existing restorations or prostheses. Non-restorable teeth that 

    pose an infection risk in the short term should be extracted. This would include any 

    tooth affected by severe periodontal disease or deemed to be of endodontic concern. 

    Partially-erupted third molars should be evaluated and be extracted if they are at risk for 

    for pericornitis. A thorough dental prophylaxis including scaling and root planing must 

    be completed. Decreasing the existing intraoral bacterial load is one of the best 

    preventive services that can be performed for the patient scheduled to undergo 

    chemotherapy. Carious lesions and tooth-born fractures should be restored. Resin 

    modified glass ionomer is a good restorative material choice for these patients as 

    xerostomia is anticipated during cancer treatment. Any orthodontic bands and wires 

    should be removed and orthodontic treatment postponed until cancer treatment is 

    completed. Oral hygiene instructions should be reviewed, even for regular dental 

    patients. Educating about possible or anticipated oral issues and reassuring the patient 

    and the family they are not alone in this battle builds confidence and strengthens the 

    dental professional/patient relationship. 

     

    ORAL HEALTH BEFORE HEAD AND NECK RADIATION THERAPY 

     

    Radiation therapy is routinely used to treat tumors in the head or neck, often in 

    combination with chemotherapy or immunotherapy. Head and neck radiation, unlike 

    radiotherapy in other parts of the body, creates issues of particular concern for the 

    dental professional. Patients undergoing head and neck radiation therapy often 

    experience permanent life-changing side effects from their cancer treatment. 

    Understanding these complications at the pre-treatment assessment positions the 

    dental professional to be of the most service. 

     

    The pre-treatment assessment appointment for the patient undergoing head and neck 

    radiation begins with a full-mouth series of radiographs. A clinical examination including 

    complete periodontal charting must be combined with the radiographic evaluation to 

    assess periodontal condition, to diagnose periapical pathology and to identify teeth 

    requiring immediate attention. All possible sources of intraoral trauma must be 

     

    resolved. Because trauma to irradiated bone poses a risk for osteoradionecrosis, the 

    dental professional must evaluate the current condition of the teeth and periodontium 

    and anticipate the patient’s ability to maintain meticulous oral hygiene for the remainder 

    of his or her life, often in challenging intraoral conditions. All non-restorable teeth 

    should be extracted. Those teeth with moderate to severe periodontal disease and 

    partially-erupted third molars within the anticipated field of radiation should also be 

    removed. Other teeth in the planned field of radiation should be evaluated in light of the 

    patient’s current hygiene status and dental history, the presence of high-risk deleterious 

    habits or co-morbidities (e.g. smoking and diabetes mellitus), the patient’s commitment 

    to regular professional dental visits, and the risk of osteoradionecrosis. Any decision by 

    the patient to refuse to comply with the dental professional’s recommendation should be 

    well-documented in the patient’s chart. All remaining teeth must be thoroughly cleaned. 

    Dental impressions should be taken from which fluoride trays can be fabricated for the 

    patient’s at-home use. The dental professional should counsel the patient and his or 

    her family concerning the anticipated complications of head and neck radiation therapy 

    and the life-long changes that must be made in oral health care. 

     

    Communication between the dental professional and radiation oncologist is extremely 

    important. The dentist should understand the anticipated scheduling of radiation 

    treatments and must know the amount of radiation planned for each of the jaws. 

    Similarly, the radiation oncologist should be aware of all necessary dental treatment and 

    the anticipated timeline to complete it. The timing of dental surgery is of utmost 

    importance: at least 14 days should be available for healing following any surgery 

    before radiation therapy commences. The dental professional should understand that 

    tumors of the head and neck are often times fast moving and require expeditious 

    treatment. Every effort should be made to accommodate head and neck patients for 

    treatment as soon as possible. There are times, however, when the nature of the tumor 

    may be such that radiation therapy must be initiated immediately and not allow 

    adequate time for dental work to be completed. In these cases, dental care should be 

    postponed until the completion of radiotherapy and the patient has sufficiently 

    recovered. Dental care should be avoided while the patient is undergoing radiation 

    therapy, but should be completed as soon after radiotherapy as possible since bone 

    changes associated with radiation worsen over time. 

     

    ORAL HEALTH BEFORE BISPHOSPHONATE THERAPY 

     

    Bisphosphonate therapy is used extensively in patients with metastatic bone disease. 

    These drugs, which include Zometa®(zoledronic acid) and Aredia®(pamidronate), are 

    administered intravenously through a portacath. They fall into a unique class of drugs 

    that are characterized by their affinity for bone and the ability to inhibit bone resorption 

    through decreased osteoclastic activity. Because they limit bone turnover, these drugs 

    have been implicated in osteonecrosis following dental surgery subsequent to 

    bisphosphonate therapy. Drug potency and accumulation seem to be important factors 

    in assessing whether or not a patient is at risk for developing bisphosphonate-related 

    osteonecrosis of the jaw. 

     

    If non-restorable teeth exist in a patient who will be undergoing bisphosphonate therapy, 

    they should be removed at least 14 days before the introduction of the drug, if possible. 

    Partially-erupted third molars and teeth with moderate to severe periodontal disease 

    should be considered for extraction. Precautions similar to those for patients 

    undergoing head and neck radiation should be considered in evaluating teeth for 

    possible extraction as the half-life bisphosphonates can exceed ten years. All dental 

    professionals should be aware that a history of bisphosphonate disclosed in a medical 

    history should be carefully considered and evaluated to assess the risk for 

    bisphosphonate-related osteonecrosis of the jaw. 

     

    #15655
    drmithila
    Offline
    Registered On: 14/05/2011
    Topics: 242
    Replies: 579
    Has thanked: 0 times
    Been thanked: 0 times

    J. Silvio Gutkind, Ph.D., chief of the Oral and Pharyngeal Cancer Branch of the National Institute of Dental and Craniofacial Research at the National Institutes of Health, and colleagues induced premalignant lesions in laboratory mice and studied the effect of metformin on progression of these lesions to oral cancers.
    "We saw strong activity against mTORC1 (mammalian target of rapamycin complex 1), which we know contributes to oral cancers, so this is strong preclinical information that there is a protective effect," said Gutkind.
    Metformin is the most widely used treatment for patients with type 2 diabetes, and scientists have started to notice a trend toward cancer reduction in a number of organ sites.
    Gutkind and colleagues found that administration of metformin reduced the size and number of carcinogen-induced oral tumoral lesions in mice and significantly reduced the development of squamous cell carcinomas by about 70 to 90 percent.
    They found that metformin inhibited mTORC1 function in the basal layer of oral premalignancies and prevented their spontaneous development into head and neck squamous cell carcinomas.
    "We clearly saw a direct effect on premalignant lesions," said Gutkind.

     

    #15659
    drsushant
    Offline
    Registered On: 14/05/2011
    Topics: 253
    Replies: 277
    Has thanked: 0 times
    Been thanked: 0 times

    For the first time, stem cell researchers at the University of Minnesota have coaxed human embryonic stem cells to create cancer-killing cells in the laboratory, paving the way for future treatments for various types of cancers (or tumors). The research will be published in the Oct. 15 issue of the Journal of Immunology.
    Researchers generated "natural killer" cells from the human embryonic stem cells. As part of the immune system, natural killer cells normally are present in the blood stream and are play a role in defending the body against infection and against some cancers.
    "This is the first published research to show the ability to make cells from human embryonic stem cells that are able to treat and fight cancer, especially leukemias and lymphomas," said Dan Kaufman, M.D., Ph.D., assistant professor of medicine in the Stem Cell Institute and Department of Medicine at the University of Minnesota and lead author of the study.
    "We hear a lot about the potential of stem cells to treat conditions such as Parkinson’s disease, diabetes, and Alzheimer’s disease. This research suggests it is possible that we could use human embryonic stem cells as a source for immune cells that could better target and destroy cancer cells and potentially treat infections," Kaufman added.
    The results also provided the researchers with a model of how the immune system develops.
    Next, the researchers will test whether the human embryonic stem cell-derived natural killer cells can target cancer cells in animal models.
    This research was done on two of the federally approved embryonic stem cell lines. Kaufman said, however, that if the research would lead to a treatment for people, new lines would have to be developed. The research was funded by the National Institutes of Health and the American Society of Hematology.

     

Viewing 3 posts - 1 through 3 (of 3 total)
  • You must be logged in to reply to this topic.